106-120 of 334
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiersTiming Meningococcal Vaccines in gMG: Challenges and Considerations
Michael Weiss, MD
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiersIndividualizing gMG Treatment: Defining Success With Each Patient
Omar Sinno, MD
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Charles Turck, PharmD, BCPS, BCCCP
Luhua (Michael) Wang, MD
Managing Genotype-Positive Patients in Hereditary ATTR-CM
On the Frontlines of ATTR-CMManaging Genotype-Positive Patients in Hereditary ATTR-CM
Shelina Ramnarine, PhD
Naveen L. Pereira, MD
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
NeuroFrontiersLUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiersAdvancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
- advertisement
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiersExamining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
Ryan Quigley
The Cost of Progress: Examining Barriers to ATTR-CM Care
On the Frontlines of ATTR-CMThe Cost of Progress: Examining Barriers to ATTR-CM Care
Charles Turck, PharmD, BCPS, BCCCP
Michelle Kittleson, MD, PhD
Diagnostic Gaps in ATTR-CM: Insights from a Multispecialty Survey in France
Heart MattersDiagnostic Gaps in ATTR-CM: Insights from a Multispecialty Survey in France
ATTR-CM Care: Impact of Vutrisiran on Survival and Cardiovascular Events
Heart MattersATTR-CM Care: Impact of Vutrisiran on Survival and Cardiovascular Events
Ryan Quigley
Improving Risk Stratification in Lupus Nephritis: The Role of Urinary Biomarkers
Living RheumImproving Risk Stratification in Lupus Nephritis: The Role of Urinary Biomarkers
Vutrisiran for ATTR-CM: Impacts on Functional Capacity and Quality of Life
On the Frontlines of ATTR-CMVutrisiran for ATTR-CM: Impacts on Functional Capacity and Quality of Life
Ryan Quigley
Farooq Hameed Sheikh, MD
- advertisement
Saliva as a Window Into Cystic Fibrosis: Metabolic Biomarkers and Clinical Potential
Clinician's RoundtableSaliva as a Window Into Cystic Fibrosis: Metabolic Biomarkers and Clinical Potential
Ryan Quigley
Advances in Disease-Modifying and Curative Therapies for Sickle Cell Disease
Project Oncology®Advances in Disease-Modifying and Curative Therapies for Sickle Cell Disease
Alexis Leonard
CRISPR in Sickle Cell: Transforming Care Through Gene Editing
Project Oncology®CRISPR in Sickle Cell: Transforming Care Through Gene Editing
Alexis Leonard
